LBT Innovations Limited

Equities

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E. 21:52:45 2024-06-19 EDT 5-day change 1st Jan Change
0.018 AUD +12.50% Intraday chart for LBT Innovations Limited +38.46% +63.64%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
LBT Innovations Sells APAS Independence Instrument to NovaCina MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79% MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31% MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023 CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring MT
LBT Innovations Fully Repays Share Placement Facility MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27% MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11% MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
LBT Innovations Flags AU$13 Million Impairment Charge MT
LBT Innovations Limited Appoints Rebecca Wilson as Director CI
LBT Innovations Appoints Chair; Shares Jump 7% MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Transcript : LBT Innovations Limited, Q2 2023 Earnings Call, Jan 25, 2023
LBT Innovations, AstraZeneca Partner to Develop APAS Pharma Product MT
Astrazeneca Partners LBT for Apas Pharma Development CI
LBT Innovations Limited Receives an Initial Purchase Order from Thermo Fisher Scientific, Inc CI
LBT Innovations Subsidiary Appoints Thermo Fisher as Exclusive Distributor for Europe MT
Chart LBT Innovations Limited
More charts
LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.
More about the company
  1. Stock Market
  2. Equities
  3. LBT Stock
  4. News LBT Innovations Limited
  5. LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher